- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Delusional Disorder.
Displaying page 1 of 1.
EudraCT Number: 2006-007019-25 | Sponsor Protocol Number: Delusional Parasitosis 1/Dec 2006 | Start Date*: 2008-01-21 | |||||||||||
Sponsor Name:Barts and the London NHS Trust | |||||||||||||
Full Title: Pilot open trial of efficacy of Risperidone in Delusional Parasitosis | |||||||||||||
Medical condition: Delusional Parasitosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011343-39 | Sponsor Protocol Number: RIS-SCH-4226 | Start Date*: 2009-06-15 | |||||||||||||||||||||||||||||||
Sponsor Name:Janssen-Cilag AB | |||||||||||||||||||||||||||||||||
Full Title: Patient and physician preferences and satisfaction with oral and long-acting injectable long-term antipsychotic treatment for psychotic disorders | |||||||||||||||||||||||||||||||||
Medical condition: Schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorder NOS or any other psychotic disorder patients demanding long term antipsychotic treatment | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000709-36 | Sponsor Protocol Number: 15/0947 | Start Date*: 2016-11-23 | ||||||||||||||||||||||||||
Sponsor Name:UCL | ||||||||||||||||||||||||||||
Full Title: Research into Antipsychotic Discontinuation and Reduction (RADAR): A Randomised Controlled Trial | ||||||||||||||||||||||||||||
Medical condition: Schizophrenia, delusional disorders, schizoaffective disorder, psychosis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-007127-40 | Sponsor Protocol Number: D1443L00048 | Start Date*: 2008-09-10 |
Sponsor Name:Astra ZenecaGmbH | ||
Full Title: CARE II - Evaluation of treatment outcomes in schizophrenic patients taking part in the integrated care program - a single-country, multi-centre phase IV study | ||
Medical condition: Symptomatic schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder or psychotic disorder not otherwise specified | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-003834-21 | Sponsor Protocol Number: 80-83600-98-10086 | Start Date*: 2016-09-23 |
Sponsor Name:Erasmus Medical Center Rotterdam | ||
Full Title: Effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: an open label randomized controlled trial. | ||
Medical condition: Psychotic disorders | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000053-27 | Sponsor Protocol Number: MELIA | Start Date*: 2020-07-09 |
Sponsor Name:UMC Utrecht | ||
Full Title: The MEtformin-LIfestyle in Antipsychotic users trial (MELIA): optimizing the use of metformin in the management of antipsychotic-induced weight gain. | ||
Medical condition: Antipsychotic-induced weight gain (AiWG) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000256-33 | Sponsor Protocol Number: Ra-P-OCD-01 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement | |||||||||||||
Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001069-32 | Sponsor Protocol Number: D1449L0001 | Start Date*: Information not available in EudraCT |
Sponsor Name:Psychosis Early Detection and Intervention Centre, Department for Psychiatry, UKE Hamburg | ||
Full Title: A prospective 8 weeks acute phase-IV study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years | ||
Medical condition: A prospective 8 weeks acute phase study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005004-13 | Sponsor Protocol Number: NEURAPRO-E FINAL Protocol | Start Date*: 2010-10-14 |
Sponsor Name:Orygen Research Centre | ||
Full Title: Add-on Therapie mit Omega-3 Fettsäuren bei Jugendlichen mit hohem Risiko für Schizophrenie und andere psychotische Störungen: eine Multizentren- Replikationsstudie Omega-3 Fatty Acids for Symptomat... | ||
Medical condition: In view of recent data and after a careful review of potentially neuroprotective treatment options in early psychotic illness, we have decided to replicate the findings of a randomized controlled t... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002126-90 | Sponsor Protocol Number: 2019/399/HP | Start Date*: 2021-03-09 | ||||||||||||||||
Sponsor Name:Direction de la Recherche Clinique et de l’Innovation – CHU de Rouen | ||||||||||||||||||
Full Title: Opioid-Free Anesthesia in Cardiac Surgery | ||||||||||||||||||
Medical condition: Patients undergoing cardiac surgery under extracorporeal circulation with at least one aorto-coronary bypass and the removal of at least one internal mammary artery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016715-38 | Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL | Start Date*: 2010-02-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000219-18 | Sponsor Protocol Number: PsiloRCT001 | Start Date*: 2018-04-09 | ||||||||||||||||
Sponsor Name:Imperial College London | ||||||||||||||||||
Full Title: Psilocybin vs. escitalopram for major depressive disorder: comparative mechanisms | ||||||||||||||||||
Medical condition: Major Depressive Disorder | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001573-28 | Sponsor Protocol Number: Uni-Koeln-320 | Start Date*: 2007-11-26 |
Sponsor Name:Universität zu Köln | ||
Full Title: Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial. | ||
Medical condition: Persons at risk of being prodromally symptomatic of psychosis (PAR) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
